Skip to content
Screener

Xencor XNCR Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$1.25B-11.7%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
-$56.16M-84.8%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$53.01M-34.3%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
-$112.18M-33.9%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-$36.94M-77.6%
Regenxbio logo
RegenxbioRGNX
$22.7M+132%

Other financials

Income statement

See full
Revenue$51.2M+17.5%
Operating income-$37.1M-11.7%
Net income-$21.7M+29.5%
EPS (diluted)-$0.29+29.3%

Balance sheet

See full
Cash & equivalents$44.7M+0.5%
Total debt$170.1M-20.1%
Total equity$503.2M-18.9%
Total assets$725.0M-17.6%

Cash flow

See full
Operating cash flow-$55.7M-53.0%
CapEx$538.0K+40.5%
Free cash flow-$56.2M-52.9%

Valuation

See full
Market cap$1.55B+210%
Enterprise value$1.67B+150%
P/S14.7×+11.3×

Profitability

See full
Operating margin-205.8%-2,501pp
Net margin-155.6%+78.8pp
FCF margin-198.4%-1,485pp

Returns & leverage

See full
Return on equity-29.1%+0.2pp
Debt / equity0.3×0.0×
Current ratio6.4×+1.1×

Where this comes from

Reported directly by Xencor in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The source filing: Xencor’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:02 PM EDT
Fiscal quarter
Q4 FY2028
Calendar quarter
Q4 2028
Accession
0001326732-26-000056
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Net loss attributable to Xencor, Inc.$(21,729)$(30,825)$(150,645)$(79,243)
Net loss per share attributable to Xencor, Inc. (basic and diluted)$(0.29)$(0.41)$(1.99)$(1.07)
Weighted-average shares used in calculating net loss per share (basic and diluted)75,85974,27975,55573,975
Other comprehensive income (loss), net of tax:
Net unrealized (loss) gain on marketable debt securities(899)(97)(2,448)921
Comprehensive loss$(22,628)$(30,922)$(153,093)$(78,536)
Less: comprehensive loss attributable to the noncontrolling interest(214)
Comprehensive loss attributable to Xencor, Inc.$(22,628)$(30,922)$(153,093)$(78,322)

Item 1. Financial Statements

FAQ

What is Xencor's comprehensive income (loss), net of tax, attributable to parent?
Xencor (XNCR) reported comprehensive income (loss), net of tax, attributable to parent of -$22.63M in Q2 2026.
How has Xencor's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
Xencor's comprehensive income (loss), net of tax, attributable to parent increased by 26.8% year-over-year, from -$30.92M to -$22.63M.
What is the long-term trend for Xencor's comprehensive income (loss), net of tax, attributable to parent?
Over 4 years (2021 to 2025), Xencor's comprehensive income (loss), net of tax, attributable to parent has grown at a 2.6% compound annual growth rate (CAGR), from $81.05M to -$89.68M.
What does comprehensive income (loss), net of tax, attributable to parent mean?
This metric reflects the total change in equity from non-owner sources, encompassing both net income and other comprehensive income items such as unrealized gains or losses on securities. It provides a more holistic view of financial performance by including items that bypass the traditional income statement. Investors use this to assess the total impact of market-driven adjustments on the company's overall financial position.

Ask your AI about Xencor's comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude